Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Abendroth

Showing results (91-100 of 104) with videos related to

Pageof 11
Sort By:
Acta Crystallographica. Section F, Structural Biology Communications|March 4, 2025
Analysis of Burkholderia pseudomallei IspF in complex with sulfapyridine, sulfamonomethoxine, ethoxzolamide and acetazolamideDakota Grote, Christopher G Stewart, Drashti G Daraji, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2010
Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge regionYu Mi Ahn, Michael Clare, Carol L Ensinger, et al.
The Journal of Biological Chemistry|June 28, 2014
Inhibition of plasma kallikrein by a highly specific active site blocking antibodyJon A Kenniston, Ryan R Faucette, Diana Martik, et al.
Journal of Medicinal Chemistry|March 18, 2015
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine CarbapenemasesScott J Hecker, K Raja Reddy, Maxim Totrov, et al.
Journal of Medicinal Chemistry|November 26, 2024
Discovery of UCB9386: A Potent, Selective, and Brain-Penetrant Nuak1 Inhibitor Suitable for <i>In Vivo</i> Pharmacological StudiesKarine G Poullennec, Eric Jnoff, Jan Abendroth, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2013
A structural biology approach enables the development of antimicrobials targeting bacterial immunophilinsDarren W Begley, David Fox, Dominic Jenner, et al.
Science Translational Medicine|September 6, 2019
Overcoming adaptive therapy resistance in AML by targeting immune response pathwaysKatelyn Melgar, Morgan M Walker, LaQuita M Jones, et al.
Protein Science : a Publication of the Protein Society|January 14, 2020
Structures of glyceraldehyde 3-phosphate dehydrogenase in Neisseria gonorrhoeae and Chlamydia trachomatisKayleigh F Barrett, David M Dranow, Isabelle Q Phan, et al.
The Journal of Antimicrobial Chemotherapy|March 4, 2022
Broad-spectrum in vitro activity of macrophage infectivity potentiator inhibitors against Gram-negative bacteria and Leishmania majorJua Iwasaki, Donald D Lorimer, Mirella Vivoli-Vega, et al.
Plos One|February 6, 2013
Combining functional and structural genomics to sample the essential Burkholderia structomeLoren Baugh, Larry A Gallagher, Rapatbhorn Patrapuvich, et al.
Pageof 11

Showing results (91-100 of 104) with videos related to

Sort By:
Pageof 11
Acta Crystallographica. Section F, Structural Biology Communications|March 4, 2025
Analysis of Burkholderia pseudomallei IspF in complex with sulfapyridine, sulfamonomethoxine, ethoxzolamide and acetazolamideDakota Grote, Christopher G Stewart, Drashti G Daraji, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2010
Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge regionYu Mi Ahn, Michael Clare, Carol L Ensinger, et al.
The Journal of Biological Chemistry|June 28, 2014
Inhibition of plasma kallikrein by a highly specific active site blocking antibodyJon A Kenniston, Ryan R Faucette, Diana Martik, et al.
Journal of Medicinal Chemistry|March 18, 2015
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine CarbapenemasesScott J Hecker, K Raja Reddy, Maxim Totrov, et al.
Journal of Medicinal Chemistry|November 26, 2024
Discovery of UCB9386: A Potent, Selective, and Brain-Penetrant Nuak1 Inhibitor Suitable for <i>In Vivo</i> Pharmacological StudiesKarine G Poullennec, Eric Jnoff, Jan Abendroth, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2013
A structural biology approach enables the development of antimicrobials targeting bacterial immunophilinsDarren W Begley, David Fox, Dominic Jenner, et al.
Science Translational Medicine|September 6, 2019
Overcoming adaptive therapy resistance in AML by targeting immune response pathwaysKatelyn Melgar, Morgan M Walker, LaQuita M Jones, et al.
Protein Science : a Publication of the Protein Society|January 14, 2020
Structures of glyceraldehyde 3-phosphate dehydrogenase in Neisseria gonorrhoeae and Chlamydia trachomatisKayleigh F Barrett, David M Dranow, Isabelle Q Phan, et al.
The Journal of Antimicrobial Chemotherapy|March 4, 2022
Broad-spectrum in vitro activity of macrophage infectivity potentiator inhibitors against Gram-negative bacteria and Leishmania majorJua Iwasaki, Donald D Lorimer, Mirella Vivoli-Vega, et al.
Plos One|February 6, 2013
Combining functional and structural genomics to sample the essential Burkholderia structomeLoren Baugh, Larry A Gallagher, Rapatbhorn Patrapuvich, et al.
Pageof 11